Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR790 + Tislelizumab in Advanced Solid Tumors
NCT05505877Phase 2Unknown
- Sponsor
- Shanghai Gopherwood Biotech
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BR790 in solid tumor (advanced stage), sponsored by Shanghai Gopherwood Biotech. Status: unknown.
02
Drugs
BR790
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05505877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505877.